Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Canaccord Calls Doximity, Inc. (DOCS)'s Post-Earnings Selloff an Overreaction And Sees Long-Term Upside

Canaccord Calls Doximity, Inc. (DOCS)'s Post-Earnings Selloff an Overreaction And Sees Long-Term Upside

FinvizFinviz2026/02/18 06:15
By:Finviz

Doximity, Inc. (NYSE:DOCS) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Canaccord Calls Doximity, Inc. (DOCS)'s Post-Earnings Selloff an Overreaction And Sees Long-Term Upside image 0

The stock given seventh position on our list of best healthcare stocks is Doximity, Inc. (NYSE:DOCS).

TheFly reported on February 9 that Canaccord Genuity upgraded DOCS from Hold to Buy and lowered the price target to $34 from $48. The post-earnings selloff, according to the firm, was an overreaction to immediate worries about how policy and pricing uncertainties might impact pharmaceutical budgets. It was wise to draw a line and upgrade the company, according to Canaccord, which also predicted that DOCS shares would rise sharply over the course of the upcoming year as pharmaceutical budgets level off, offering a longer-term buying opportunity.

Moreover, Doximity, Inc. (NYSE:DOCS) announced its fiscal Q3 2026 results on February 5. The company's revenue for the quarter ending December 31, 2025, was $185.1 million, a 10% rise over the previous year. While net income reached $61.6 million, suggesting a 33% margin, adjusted EBITDA climbed 9% to $111.4 million, with margins staying at 60%. According to the company, platform engagement reached all-time highs, with 720,000 active users for workflow solutions and over 300,000 people using AI features. CEO Jeff Tangney claims that platform utility has increased as a result of AI integration.

In addition, the company authorized a $500 million stock repurchase program, which underscores confidence in long-term value creation. DOCS also provided guidance for Q4 and full fiscal 2026, projecting revenues of approximately $643 million and adjusted EBITDA near $356 million.

Doximity, Inc. (NYSE:DOCS) is a U.S. digital healthcare platform connecting medical professionals with secure networking, telehealth, AI‑powered workflow tools, and clinical insights. It innovates by embedding AI, telemedicine, and productivity tools into a unified physician‑centric ecosystem that streamlines care delivery, communication, and administrative tasks.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Dell executive: "Agent AI" is different this time, key components (mainly memory and HDD) shortages may last for more than 5 years

Dell Technologies Chief Operating Officer Jeff Clarke stated that proxy AI, by taking on more tasks, continues to drive up computing and storage demands, making this AI infrastructure cycle distinct from traditional hardware upgrade cycles. By 2030, data center computing power is expected to increase by 200 GW, inference token generation will grow 87-fold, and infrastructure demand is likely to continue expanding.

华尔街见闻•2026/09/25 04:01

Morgan Stanley Backs Meta (META.US): Muse Ecosystem Continues to Expand, VR Glasses Expected to Become a New Growth Point in 2027

Morgan Stanley maintains an "Overweight" rating on Meta with a target price of $775, and continues to list it as a top pick.

智通财经•2026/09/25 04:01